SGMT · Sagimet Biosciences Inc.

Track SGMT — free

$10.88 -0.18 (-1.63%) At close · Sep 11

Russell 2000 member Rebalance outlook locked

Market Cap

$676.29M

62.16M

Up next

Next earnings call

Mar 26, 2027 Est · unconfirmed · in 28 wks

Latest filing: 10-Q

filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$47.08M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

-1,537.0%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$240.13M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+65.0%

Year over year · more shares

Price change (1Y)

+55.1%

Trailing year

Short interest

16.3%

Latest settlement · 9.6 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Limited Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.60

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +58%

above

Price vs 50-day avg +22%

above

RSI (14) 63

neutral

MACD trend Negative

52-week position 97%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +17%

trailing

6-month return +126%

trailing

YTD return +84%

this year

Relative strength +108%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $9 › 200d $7 — 50d above 200d

Institutional flow Accumulating

+40% holders QoQ · +58 funds added

Insider flow Distributing

Net -$578.9K over 90 days · 100% sells

Short interest Falling

16.27% of float · ▼ -13.9% MoM · 9.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

123 holders — near 3-yr high, broad support

Squeeze score 74

high risk · 0–100

Fundamentals

Limited

Not enough data for a confident read.

Quant / Vol

risk profile

Very High

Volatility 85%

annualized · 1-yr

Max drawdown −50%

past year

ATR 5.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+58% Bullish

Price vs 50-day avg

+22% Bullish

RSI (14)

63 Neutral

MACD trend

Negative Bearish

52-week position

97% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $9 › 200d $7 — 50d above 200d

Institutional flow Accumulating

+40% holders QoQ · +58 funds added

Insider flow Distributing

Net -$578.9K over 90 days · 100% sells

Short interest Falling

16.27% of float · ▼ -13.9% MoM · 9.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

123 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $5 Now $11 · 97% Range high $11

vs 200-day avg +58% vs 50-day avg +22%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
SGMT Sagimet Biosciences Inc. this stock	$676.29M	+83.8%	—	—	16.3%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.64B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$80.46B	+1.2%	+20.8%	19.4	2.5%
ARGX Argenx SE	$61.60B	+17.1%	—	—	2.0%
MRNA Moderna, Inc.	$57.48B	+388.2%	+4.3%	—	9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

123

% held: 83.2%
Net QoQ: +38.0M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

10.1M

Days to cover: 9.6d
Change: -1.6M sh

View

Short Volume

Short vol %

52%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

1.2K

Value: $11.0K
As of: Aug 11, 2026

View

Off-Exchange

Off-exchange %

42.6%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$578.9K

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Financials

Revenue (FY)

$2.0M

Net income (FY): $-51.0M
EPS diluted: $-1.58

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 13, 2026
This year: 17

View

Proposed Sales

Value

$3.3M

Shares: 351.0K
Filed: Aug 14, 2026

View

Exempt Offerings

Offering

$80.0M

Filed: Jan 5, 2021

View

Earnings & Events

Earnings Calls

Last call

Sep 9, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
SGMT	-0.4%	+17.2%	+125.7%	+6.0%	+83.8%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	+0.8%	+19.0%	+107.9%	+6.4%	+71.7%

Key facts CIK 1400118 CUSIP 786700104 13F (30d) 74 filings 74 filers Visit website Investor relations

SGMT · Sagimet Biosciences Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance